The ameliorating effects of apigenin and chrysin alone and in combination on polycystic ovary syndrome induced by dehydroepiandrosterone in rats

Buket Berk; Nevin İlhan; Solmaz Susam; Fatma Tedik; Nalan Kaya Tektemur

Makale detayları

The ameliorating effects of apigenin and chrysin alone and in combination on polycystic ovary syndrome induced by dehydroepiandrosterone in rats

Yazarlar:

Buket Berk | Nevin İlhan | Solmaz Susam | Fatma Tedik | Nalan Kaya Tektemur

Yayıncı:

Marmara University

Ana Başlıklar:

Surgery (Other)

Dergi:

Marmara Medical Journal Vol.37 Issue 2, pp.198-207

Belge Tipi:

Makale

Yayın Tarihi:

5/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001317360

pISSN:

1019-1941

Anahtar kelimeler:

Özet:

 Objective: Polycystic ovary syndrome PCOS is the most common endocrine disorder among women of reproductive age and is one of the main causes of ovulation infertility, affecting 5-10 of women. Inflammation, hormonal imbalances, and disruption of the oxidant-antioxidant balance are the main factors in the pathophysiology of PCOS. This study was designed to answer the question of whether apigenin and chrysin have therapeutic effects on the dehydroepiandrosterone DHEA-induced rat model of PCOS. Materials and Methods: The experimental PCOS model was created by administering 6 mg100g DHEA subcutaneously to 21-day-old female Wistar rats for 28 days, followed by treatment with natural agents 50 mgkg apigenin and 50 mgkg chrysin by oral gavage twice a week for one month. The predominant cell type was determined by microscopic analysis in vaginal smears daily from day 10 to day 28 of the experiment. In tissue supernatants, superoxide dismutase SOD, catalase CAT, glutathione peroxidase GPx activities, and malondialdehyde MDA levels were obtained by spectrophotometric method with appropriate manual methods; follicle-stimulating hormone FSH, luteinizing hormone LH, progesterone, interleukin IL-18, IL-1β, and IL-13 levels were determined by enzymelinked immunosorbent assay ELISA method. In addition, histological sections obtained from ovarian tissue samples were stained with hematoxylin-eosin and examined under a light microscope. Results: The results showed that treatment with apigenin and chrysin alone and in combination reduced MDA, LH, FSH, progesterone, IL-1β, IL-13, and IL-18 levels compared with PCOS rats. Furthermore, enzymatic activities of antioxidants including CAT, SOD, and GPx in the ovaries increased in therapeutic groups compared to the PCOS group. Conclusion: In conclusion, this study demonstrates the potential therapeutic efficacy of apigenin and chrysin, either alone or in combination, in alleviating the hormonal imbalances, inflammation, and oxidative stress in DHEA-induced PCOS rats. Apigenin, in particular, emerges as a promising agent for PCOS treatment, showing superiority over chrysin and combination treatments in ameliorating cystic follicles and improving various parameters associated with PCOS pathophysiology. These findings suggest that apigenin holds promise as a novel therapeutic agent for PCOS and warrants further investigation in clinical settings.

 Objective: Polycystic ovary syndrome PCOS is the most common endocrine disorder among women of reproductive age and is one of the main causes of ovulation infertility, affecting 5-10 of women. Inflammation, hormonal imbalances, and disruption of the oxidant-antioxidant balance are the main factors in the pathophysiology of PCOS. This study was designed to answer the question of whether apigenin and chrysin have therapeutic effects on the dehydroepiandrosterone DHEA-induced rat model of PCOS. Materials and Methods: The experimental PCOS model was created by administering 6 mg100g DHEA subcutaneously to 21-day-old female Wistar rats for 28 days, followed by treatment with natural agents 50 mgkg apigenin and 50 mgkg chrysin by oral gavage twice a week for one month. The predominant cell type was determined by microscopic analysis in vaginal smears daily from day 10 to day 28 of the experiment. In tissue supernatants, superoxide dismutase SOD, catalase CAT, glutathione peroxidase GPx activities, and malondialdehyde MDA levels were obtained by spectrophotometric method with appropriate manual methods; follicle-stimulating hormone FSH, luteinizing hormone LH, progesterone, interleukin IL-18, IL-1β, and IL-13 levels were determined by enzymelinked immunosorbent assay ELISA method. In addition, histological sections obtained from ovarian tissue samples were stained with hematoxylin-eosin and examined under a light microscope. Results: The results showed that treatment with apigenin and chrysin alone and in combination reduced MDA, LH, FSH, progesterone, IL-1β, IL-13, and IL-18 levels compared with PCOS rats. Furthermore, enzymatic activities of antioxidants including CAT, SOD, and GPx in the ovaries increased in therapeutic groups compared to the PCOS group. Conclusion: In conclusion, this study demonstrates the potential therapeutic efficacy of apigenin and chrysin, either alone or in combination, in alleviating the hormonal imbalances, inflammation, and oxidative stress in DHEA-induced PCOS rats. Apigenin, in particular, emerges as a promising agent for PCOS treatment, showing superiority over chrysin and combination treatments in ameliorating cystic follicles and improving various parameters associated with PCOS pathophysiology. These findings suggest that apigenin holds promise as a novel therapeutic agent for PCOS and warrants further investigation in clinical settings.

 Objective: Polycystic ovary syndrome PCOS is the most common endocrine disorder among women of reproductive age and is one of the main causes of ovulation infertility, affecting 5-10 of women. Inflammation, hormonal imbalances, and disruption of the oxidant-antioxidant balance are the main factors in the pathophysiology of PCOS. This study was designed to answer the question of whether apigenin and chrysin have therapeutic effects on the dehydroepiandrosterone DHEA-induced rat model of PCOS. Materials and Methods: The experimental PCOS model was created by administering 6 mg100g DHEA subcutaneously to 21-day-old female Wistar rats for 28 days, followed by treatment with natural agents 50 mgkg apigenin and 50 mgkg chrysin by oral gavage twice a week for one month. The predominant cell type was determined by microscopic analysis in vaginal smears daily from day 10 to day 28 of the experiment. In tissue supernatants, superoxide dismutase SOD, catalase CAT, glutathione peroxidase GPx activities, and malondialdehyde MDA levels were obtained by spectrophotometric method with appropriate manual methods; follicle-stimulating hormone FSH, luteinizing hormone LH, progesterone, interleukin IL-18, IL-1β, and IL-13 levels were determined by enzymelinked immunosorbent assay ELISA method. In addition, histological sections obtained from ovarian tissue samples were stained with hematoxylin-eosin and examined under a light microscope. Results: The results showed that treatment with apigenin and chrysin alone and in combination reduced MDA, LH, FSH, progesterone, IL-1β, IL-13, and IL-18 levels compared with PCOS rats. Furthermore, enzymatic activities of antioxidants including CAT, SOD, and GPx in the ovaries increased in therapeutic groups compared to the PCOS group. Conclusion: In conclusion, this study demonstrates the potential therapeutic efficacy of apigenin and chrysin, either alone or in combination, in alleviating the hormonal imbalances, inflammation, and oxidative stress in DHEA-induced PCOS rats. Apigenin, in particular, emerges as a promising agent for PCOS treatment, showing superiority over chrysin and combination treatments in ameliorating cystic follicles and improving various parameters associated with PCOS pathophysiology. These findings suggest that apigenin holds promise as a novel therapeutic agent for PCOS and warrants further investigation in clinical settings.

 Objective: Polycystic ovary syndrome PCOS is the most common endocrine disorder among women of reproductive age and is one of the main causes of ovulation infertility, affecting 5-10 of women. Inflammation, hormonal imbalances, and disruption of the oxidant-antioxidant balance are the main factors in the pathophysiology of PCOS. This study was designed to answer the question of whether apigenin and chrysin have therapeutic effects on the dehydroepiandrosterone DHEA-induced rat model of PCOS. Materials and Methods: The experimental PCOS model was created by administering 6 mg100g DHEA subcutaneously to 21-day-old female Wistar rats for 28 days, followed by treatment with natural agents 50 mgkg apigenin and 50 mgkg chrysin by oral gavage twice a week for one month. The predominant cell type was determined by microscopic analysis in vaginal smears daily from day 10 to day 28 of the experiment. In tissue supernatants, superoxide dismutase SOD, catalase CAT, glutathione peroxidase GPx activities, and malondialdehyde MDA levels were obtained by spectrophotometric method with appropriate manual methods; follicle-stimulating hormone FSH, luteinizing hormone LH, progesterone, interleukin IL-18, IL-1β, and IL-13 levels were determined by enzymelinked immunosorbent assay ELISA method. In addition, histological sections obtained from ovarian tissue samples were stained with hematoxylin-eosin and examined under a light microscope. Results: The results showed that treatment with apigenin and chrysin alone and in combination reduced MDA, LH, FSH, progesterone, IL-1β, IL-13, and IL-18 levels compared with PCOS rats. Furthermore, enzymatic activities of antioxidants including CAT, SOD, and GPx in the ovaries increased in therapeutic groups compared to the PCOS group. Conclusion: In conclusion, this study demonstrates the potential therapeutic efficacy of apigenin and chrysin, either alone or in combination, in alleviating the hormonal imbalances, inflammation, and oxidative stress in DHEA-induced PCOS rats. Apigenin, in particular, emerges as a promising agent for PCOS treatment, showing superiority over chrysin and combination treatments in ameliorating cystic follicles and improving various parameters associated with PCOS pathophysiology. These findings suggest that apigenin holds promise as a novel therapeutic agent for PCOS and warrants further investigation in clinical settings.

Makale detayları

The ameliorating effects of apigenin and chrysin alone and in combination on polycystic ovary syndrome induced by dehydroepiandrosterone in rats

Yazarlar:

Buket Berk | Nevin İlhan | Solmaz Susam | Fatma Tedik | Nalan Kaya Tektemur

Yayıncı:

Marmara University

Ana Başlıklar:

Surgery (Other)

Dergi:

Marmara Medical Journal Vol.37 Issue 2, pp.198-207

Belge Tipi:

Makale

Yayın Tarihi:

5/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001317360

pISSN:

1019-1941

Polycystic ovary syndrome

Dehydroepiandrosterone

Apigenin

Chrysin

Sayı

Makale detayları

The ameliorating effects of apigenin and chrysin alone and in combination on polycystic ovary syndrome induced by dehydroepiandrosterone in rats

Yazarlar: Buket Berk | Nevin İlhan | Solmaz Susam | Fatma Tedik | Nalan Kaya Tektemur

Yayıncı: Marmara University

Ana Başlıklar: Surgery (Other)

Dergi: Marmara Medical Journal Vol.37 Issue 2, pp.198-207

Belge Tipi: Makale

Yayın Tarihi: 5/2024

Belge Dili: İngilizce

Document ID (Org No.): 2001317360

pISSN: 1019-1941

Polycystic ovary syndrome

Dehydroepiandrosterone

Apigenin

Chrysin

Sayı

Yazarlar:

Buket Berk | Nevin İlhan | Solmaz Susam | Fatma Tedik | Nalan Kaya Tektemur

Yayıncı:

Marmara University

Ana Başlıklar:

Surgery (Other)

Dergi:

Marmara Medical Journal Vol.37 Issue 2, pp.198-207

Belge Tipi:

Makale

Yayın Tarihi:

5/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001317360

pISSN:

1019-1941